Are Shortage Drugs Really Out of Stock? Unveiling the Supply Chain Logic Behind “Hidden Inventory”

In recent years, drug shortages have become a growing concern among patients and healthcare professionals alike.

The 2026–2028 Provincial Essential Drug Shortage Reserve Project recently underwent on-site inspection and acceptance. Under the rigorous evaluation of the Guangdong Provincial Government inspection team, Sinopharm Guangzhou successfully fulfilled its reserve responsibilities. Its emergency medical supply reserves and regional public health support capabilities once again received official recognition.

However, within the actual pharmaceutical distribution system, an often-overlooked phenomenon is drawing increasing attention: some drugs that are widely perceived as being “in shortage” are not truly unavailable nationwide. Instead, they may still exist within the supply chain as a certain amount of “hidden inventory.”

So why do drug shortages occur? Which medicines may actually have “hidden inventory”? And how can patients scientifically and legally locate available supplies?

Drug Shortages Do Not Necessarily Mean There Are No Drugs Available Nationwide

Many patients assume that a drug shortage means:

“The manufacturer has stopped producing the medicine, so it is completely unavailable on the market.”

In reality, this is only one type of shortage.

Based on practical experience within pharmaceutical supply chains, drug shortages can generally be categorized into three types:

Type 1: Genuine Production Shortages

These occur when drug supply is reduced due to disruptions in raw material availability, complex manufacturing processes, limited production capacity, or factory shutdowns.

Examples include:

● Raw material suppliers exiting the market;

● Production line upgrades resulting in temporary suspension;

● International supply chain disruptions;

● Product recalls due to quality issues.In such cases, the drug may experience prolonged nationwide shortages, with inventories gradually being depleted.

Type 2: Distribution-Related Shortages

The drug is still being manufactured, but uneven distribution across regions results in localized shortages.

For example:

● One province has sufficient inventory;

● Hospitals in another province are unable to procure the drug for an extended period;

● Large tertiary hospitals are out of stock;

● Certain specialty hospitals still maintain inventory.This situation is relatively common among imported innovative medicines and rare disease therapies.

Type 3: Information-Based Shortages

This type of shortage has become increasingly common in recent years.

Patients often have limited access to drug availability information and can only check inventory through a specific hospital or nearby pharmacy. When one institution reports that a medicine is unavailable, patients may mistakenly assume that it is out of stock nationwide.

In reality, inventory may still exist in:

● Hospitals in other cities;

● DTP pharmacies;

● Specialty medical institutions;

● Regional distribution centers;

● Pharmaceutical wholesalers and commercial inventory systems.Although these inventories exist, they may not be easily visible to patients, resulting in what is known as “hidden inventory.”

What Is “Hidden Inventory” in Drug Shortages?

“Hidden inventory” does not refer to drugs being intentionally stockpiled.

Rather, it refers to inventory that exists within the market but remains inaccessible to patients due to limited transparency, fragmented distribution channels, or procurement restrictions.

Common sources include:

DTP Pharmacy Inventory

As the market for innovative medicines and specialty drugs continues to expand, many high-value therapies are gradually shifting from hospital dispensing systems to out-of-hospital distribution channels.

As a result, some medicines that appear unavailable in hospital pharmacies may still be in stock at professional DTP pharmacies.

These commonly include:

● Targeted therapies;

● Immunotherapy drugs;

●       Rare disease treatments;

●       Biologic products.

Patients who only inquire through hospital channels may therefore mistakenly conclude that a medicine has been discontinued or is unavailable.

Regional Warehouse Inventory

Some pharmaceutical companies adopt centralized regional distribution models.

In these cases, medicines are not stored directly within hospitals but are held in regional logistics centers.

Products are dispatched only after a valid prescription is issued.

Therefore:

Out of stock at the hospital pharmacy ≠ unavailable drug supply.

Commercial Distribution Inventory

Large pharmaceutical distributors typically maintain a certain level of safety stock.

Because these inventories are not publicly accessible, patients often have no visibility into their availability.

During lengthy hospital procurement cycles, medicines may still be available through commercial distribution channels.

Inventory Accessible Through Special Import Pathways

Some innovative medicines have already been approved overseas but have not yet entered conventional distribution channels in China.

Under compliant regulatory frameworks, certain medical institutions may obtain these products through:

● Clinical urgent-use import programs;

● The Hainan Boao Lecheng International Medical Tourism Pilot Zone;

● Designated medical institutions within the Guangdong-Hong Kong-Macao Greater Bay Area.For many patients, these channels effectively represent “invisible inventory.”

How Can Patients Locate Potentially Available Inventory During Drug Shortages?

First and foremost, patients should avoid stockpiling medications unnecessarily.

Excessive purchasing not only increases financial burden but may also worsen localized supply shortages.

The following approaches are generally recommended:

Consult Licensed DTP Pharmacies

Many specialty medicines and innovative therapies are primarily supplied through DTP pharmacy networks.

Patients can consult their physicians or pharmacists regarding designated pharmacy locations.

Contact Pharmaceutical Manufacturers

Many pharmaceutical companies operate patient support service centers.

These companies often have access to information regarding:

● Supply status;

● Distribution regions;

● Partner pharmacy networks.As a result, they may be able to provide more accurate guidance on where medications are available.

Learn About Urgent Clinical Need Programs

For medicines that are not yet approved domestically or are facing supply constraints, patients may consider information regarding:

● Hainan Boao Lecheng International Medical Tourism Pilot Zone;

● Designated medical institutions within the Guangdong-Hong Kong-Macao Greater Bay Area;

●National policies governing urgently needed imported medicines.

Utilize Professional Pharmaceutical Service Platforms

Professional pharmaceutical service organizations can help patients verify drug sources, assess supply availability, and connect with compliant access channels.

As a company deeply engaged in the global supply of innovative medicines and rare disease therapies, DengYue Pharmaceutical leverages an extensive domestic and international pharmaceutical distribution network together with professional medication support services. The company assists patients in tracking drug supply updates, verifying medication accessibility, and identifying compliant pathways for obtaining treatment based on individual needs.

For innovative medicines and rare disease therapies that face supply constraints or involve complex distribution channels, such professional support services can help shorten the time required to locate available medication and improve access efficiency.

For patients with rare diseases, cancer, or those requiring long-term innovative therapies, obtaining accurate drug availability information through professional pharmaceutical service platforms can often reduce treatment delays caused by information asymmetry.

Conclusion

Within today’s pharmaceutical supply system, a patient’s ability to obtain medication depends not only on manufacturing capacity but also on distribution efficiency, information transparency, and channel accessibility.

Therefore, a “drug shortage” does not always mean that a medicine is completely unavailable.

Some products may temporarily disappear from patients’ immediate view while still remaining within different segments of the supply chain.

As digital supply chain systems and pharmaceutical information-sharing mechanisms continue to improve, the management of drug shortages is expected to evolve from a model of “searching for medicine” toward one of “precise matching,” enabling more patients to gain timely access to the treatments they need.